Shares of Envista Holdings Co. (NYSE:NVST – Get Free Report) have been assigned an average rating of “Hold” from the fifteen research firms that are presently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a sell recommendation, nine have given a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $19.63.
A number of analysts recently commented on NVST shares. Needham & Company LLC reiterated a “hold” rating on shares of Envista in a report on Thursday, August 8th. Wells Fargo & Company started coverage on shares of Envista in a report on Tuesday, October 8th. They issued an “equal weight” rating and a $20.00 target price on the stock. JPMorgan Chase & Co. downgraded shares of Envista from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $23.00 to $16.00 in a report on Thursday, August 8th. Bank of America dropped their target price on shares of Envista from $22.00 to $19.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. Finally, Robert W. Baird dropped their target price on shares of Envista from $19.00 to $17.00 and set a “neutral” rating on the stock in a report on Monday, July 22nd.
Get Our Latest Report on Envista
Envista Price Performance
Envista (NYSE:NVST – Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The company reported $0.11 EPS for the quarter, missing analysts’ consensus estimates of $0.27 by ($0.16). Envista had a positive return on equity of 4.86% and a negative net margin of 52.25%. The company had revenue of $633.10 million for the quarter, compared to the consensus estimate of $646.88 million. During the same quarter last year, the firm posted $0.43 earnings per share. The firm’s quarterly revenue was down 4.4% compared to the same quarter last year. Equities research analysts expect that Envista will post 0.69 EPS for the current fiscal year.
Insider Activity at Envista
In related news, CFO Eric D. Hammes acquired 24,532 shares of the stock in a transaction that occurred on Monday, August 12th. The shares were purchased at an average cost of $16.33 per share, with a total value of $400,607.56. Following the completion of the transaction, the chief financial officer now owns 24,532 shares of the company’s stock, valued at approximately $400,607.56. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. 1.30% of the stock is currently owned by insiders.
Institutional Trading of Envista
Several large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in Envista by 5.8% in the fourth quarter. Vanguard Group Inc. now owns 17,167,767 shares of the company’s stock worth $413,056,000 after acquiring an additional 944,596 shares in the last quarter. Ariel Investments LLC grew its position in Envista by 11.0% in the second quarter. Ariel Investments LLC now owns 9,871,152 shares of the company’s stock worth $164,157,000 after acquiring an additional 978,952 shares in the last quarter. Nuance Investments LLC grew its position in Envista by 47.2% in the second quarter. Nuance Investments LLC now owns 7,038,313 shares of the company’s stock worth $117,048,000 after acquiring an additional 2,256,993 shares in the last quarter. American Century Companies Inc. grew its position in Envista by 15.4% in the second quarter. American Century Companies Inc. now owns 6,726,651 shares of the company’s stock worth $111,864,000 after acquiring an additional 897,141 shares in the last quarter. Finally, Jupiter Asset Management Ltd. bought a new stake in Envista in the second quarter worth approximately $69,534,000.
Envista Company Profile
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
Further Reading
- Five stocks we like better than Envista
- Ride Out The Recession With These Dividend Kings
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- Stock Market Upgrades: What Are They?
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.